NCT04510129 A Multicenter Cancer Biospecimen Collection Study
| NCT ID | NCT04510129 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cofactor Genomics, Inc. |
| Condition | Cancer of Head and Neck |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,650 participants |
| Start Date | 2020-02-05 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,650 participants in total. It began in 2020-02-05 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent studies for the development and validation of a diagnostic test.
Eligibility Criteria
Inclusion Criteria: 1. Subject must have a disease of interest. Specifically, subject must have one of: 1. head and neck squamous cell carcinoma (HNSCC) 2. non-small-cell lung cancer (NSCLC) 3. small cell lung cancer (SCLC) 4. urothelial carcinoma (UCC) 5. gastric or gastroesophageal junction adenocarcinoma 6. cervical cancer 7. esophageal squamous cell carcinoma (ESCC) 8. triple-negative breast cancer (TNBC) 9. hepatocellular carcinoma (HCC) 10. renal cell carcinoma (RCC) 11. colorectal cancer (CRC) 2. Subject must have received, or be scheduled to receive, at least one dose of anti-PD-1/PD-L1 immunotherapy for treatment of their cancer. 3. Subject must have had, or will have, a tumor biopsy prior to treatment with anti-PD-1/PD-L1 immunotherapy. 4. Subject must have undergone, or will undergo, medical imaging (e.g. CT or MRI) of the tumor prior to treatment with anti-PD-1/PD-L1 immunotherapy. 5. Willing to provide electronic informed consent per IRB-approved protocol. 6. Able to speak, read, and comprehend English fluently. 7. Subject is 18 years of age or older. 8. Subjects must have sufficient tissue available to fulfill the specimen requirements of the study. Exclusion Criteria: 1. Inability or unwillingness to provide informed consent. 2. Subject who does/did not have one of the cancers listed above (other histologies). 3. Subject has already participated in this trial.
Contact & Investigator
Jarret Glasscock
STUDY DIRECTOR
Cofactor Genomics
Frequently Asked Questions
Who can join the NCT04510129 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer of Head and Neck. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04510129 currently recruiting?
Yes, NCT04510129 is actively recruiting participants. Contact the research team at clinicaltrials@cofactorgenomics.com for enrollment information.
Where is the NCT04510129 trial being conducted?
This trial is being conducted at San Francisco, United States.
Who is sponsoring the NCT04510129 clinical trial?
NCT04510129 is sponsored by Cofactor Genomics, Inc.. The principal investigator is Jarret Glasscock at Cofactor Genomics. The trial plans to enroll 1,650 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.